Company / Capital Expenditures
ALNYLAM PHARMACEUTICALS, INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$58.7M
FY2025
5-year range
$34.3M / $140.2M
FY2021-FY2025
Trend
+71.2%
vs FY2024
Sector context
#26 of 194
Health Care
What the data says
ALNYLAM PHARMACEUTICALS, INC.'s capital expenditures of $59M is higher than 87% of companies in the Health Care sector (FY2025). Capital Expenditures returned to growth in FY2025 after 3 years of decline, reaching $59M.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of -14.3%. Top quartile in the Health Care sector.
Declined from $62M to $59M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -5.9%
- 5-Year CAGR
- -14.3%
- 10-Year CAGR
- -
Sector benchmark
-50.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.3%, indicating a declining trend.
- In FY2025, capital expenditures increased 71.2% year-over-year.
- Ranks #26 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.7M | +71.2% |
| FY2024 | $34.3M | -44.9% |
| FY2023 | $62.2M | -11.6% |
| FY2022 | $70.4M | -49.8% |
| FY2021 | $140.2M | +10.5% |
| FY2020 | $126.9M | +21.8% |
| FY2019 | $104.2M | +61.4% |
| FY2018 | $64.6M | -38.1% |
| FY2017 | $104.2M | +61.4% |
| FY2016 | $64.6M | +398.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026